Latest research on Prolia

Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption markers in patients with a variety of metastatic tumors and is being investigated in multiple clinical trials for the prevention and treatment of bone metastases. Chemically, it consists of 2 heavy and 2 light chains. Each light chain consists of 215 amino acids. Each heavy chain consists of 448 amino acids with 4 intramolecular disulfides. FDA approved on June 1, 2010.

Prolia interactions

Zometa (Novartis Pharma Stein AG) and Xgeva (GlaxoSmithKline, Amgen Manufacturing, Limited) were also given for bone metastasis. [source, 2015]
Patients are recommended to take 1000 mg oral calcium and 400 IU Vitamin D daily in the insert for Prolia. [source, 2014]
The Xgeva insert recommends the administration of calcium and Vitamin D as necessary to prevent hypocalcemia. [source, 2014]
A newer agent, Denosumab (Xgeva) which is a human monoclonal antibody that inhibits RANK ligand, has been found to be superior to the bisphosphonate Zoledronic acid in preventing skeletal-related events in patients with advanced prostate cancer and bone metastases 15. [source, 2014]
Conversely, the SBDs with the highest percentage of the maximum possible score were alemtuzumab (Mabcampath) (83.3%), denosumab (Prolia) (78.6%), cabazitaxel (Jevtana) (78.6%) and ceftobiprole (Zeftera) (78.6%). [source, 2014]
Denosumab (Prolia, XGEVA), a monoclonal antibody against RANKL, was recently demonstrated to significantly increase time to SRE compared to a bisphosphonate, Zoledronic acid, in breast and prostate cancer patients with bone disease [43, 44]. [source, 2014]
Currently, however, Zoledronic acid (Zometa, Novartis Oncology), a newer generation bisphosphonate, and denosumab (Xgeva, Amgen) are the only bone-targeted therapies that have provided solid evidence of reducing the risk for skeletal events (SREs) among men with bone metastases and a rising PSA level despite a testosterone level <50 ng/dL (castration-resistant prostate cancer (CRPC)). [source, 2013]
KOB has participated in Advisory Boards for Amgen, the makers of Xgeva and AstraZeneca, the makers of Iressa, and has received grants for translational research from these companies. [source, 2012]
In terms of cancer patients or survivors, this means we are reading more about potential relationships of Vitamin D deficiency and aromatase inhibitor–induced musculoskeletal symptoms (AIMSS) as well as cancer and cancer mortality, impaired bone health (osteoporosis or osteomalacia), and adverse effects with administration of bisphosphonates or denosumab (Prolia, Xgeva). [source, 2012]
In addition, a novel new bone-targeting monoclonal antibody, denosumab (Xgeva), and an LHRH antagonist, degarelix (Firmagon), have been introduced into clinical practice. [source, 2012]